Literature DB >> 26972981

Polycystic Liver Disease: The Benefits of Targeting cAMP.

Nicholas F Larusso1, Tatyana V Masyuk1, Marie C Hogan2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26972981      PMCID： PMC4912886          DOI： 10.1016/j.cgh.2016.03.008

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  19 in total

1.  Somatostatin analogues reduce liver volume in polycystic liver disease.

Authors:  L van Keimpema; R A de Man; J P H Drenth
Journal:  Gut       Date:  2008-09       Impact factor: 23.059

2.  Effect of octreotide on polycystic liver volume.

Authors:  Loes van Keimpema; Joost P H Drenth
Journal:  Liver Int       Date:  2009-09-09       Impact factor: 5.828

3.  Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease.

Authors:  Ramón Peces; Emilio Cuesta-López; Carlos Peces; Virginia Pérez-Dueñas; Cristina Vega-Cabrera; Rafael Selgas
Journal:  Int Urol Nephrol       Date:  2010-05-07       Impact factor: 2.370

Review 4.  Somatostatin analogues for treatment of polycystic liver disease.

Authors:  Tom J G Gevers; Joost P H Drenth
Journal:  Curr Opin Gastroenterol       Date:  2011-05       Impact factor: 3.287

5.  Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Vicente E Torres; Peter C Harris; Nicholas F Larusso
Journal:  Gastroenterology       Date:  2006-12-20       Impact factor: 22.682

6.  Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.

Authors:  Marie C Hogan; Tetyana Masyuk; Eric Bergstralh; Bill Li; Walter K Kremers; Lisa E Vaughan; Angela Ihrke; Amanda L Severson; Maria V Irazabal; James Glockner; Nicholas F LaRusso; Vicente E Torres
Journal:  Mayo Clin Proc       Date:  2015-07-09       Impact factor: 7.616

Review 7.  Therapeutic Targets in Polycystic Liver Disease.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

8.  Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

Authors:  Loes van Keimpema; Frederik Nevens; Ragna Vanslembrouck; Martijn G H van Oijen; Aswin L Hoffmann; Helena M Dekker; Robert A de Man; Joost P H Drenth
Journal:  Gastroenterology       Date:  2009-07-29       Impact factor: 22.682

9.  Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.

Authors:  Tatyana V Masyuk; Brynn N Radtke; Angela J Stroope; Jesús M Banales; Sergio A Gradilone; Bing Huang; Anatoliy I Masyuk; Marie C Hogan; Vicente E Torres; Nicholas F Larusso
Journal:  Hepatology       Date:  2013-03-06       Impact factor: 17.425

10.  Functional similarities of hepatic cystic and biliary epithelium: studies of fluid constituents and in vivo secretion in response to secretin.

Authors:  G T Everson; M Emmett; W R Brown; P Redmond; D Thickman
Journal:  Hepatology       Date:  1990-04       Impact factor: 17.425
View more
  7 in total

1.  Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.

Authors:  Maria Lorenzo Pisarello; Tatyana V Masyuk; Sergio A Gradilone; Anatoliy I Masyuk; Jingyi F Ding; Pui-Yuen Lee; Nicholas F LaRusso
Journal:  Am J Pathol       Date:  2018-01-31       Impact factor: 4.307

2.  TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Maria Lorenzo Pisarello; Brynn N Howard; Bing Q Huang; Pui-Yuen Lee; Xavier Fung; Eduard Sergienko; Robert J Ardecky; Thomas D Y Chung; Anthony B Pinkerton; Nicholas F LaRusso
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

3.  Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease.

Authors:  Kyongtae T Bae; Cheng Tao; Robert Feldman; Alan S L Yu; Vicente E Torres; Ronald D Perrone; Arlene B Chapman; Godela Brosnahan; Theodore I Steinman; William E Braun; Michal Mrug; William M Bennett; Peter C Harris; Avantika Srivastava; Douglas P Landsittel; Kaleab Z Abebe
Journal:  Clin J Am Soc Nephrol       Date:  2022-02-25       Impact factor: 10.614

4.  Autophagy promotes hepatic cystogenesis in polycystic liver disease by depletion of cholangiocyte ciliogenic proteins.

Authors:  Anatoliy I Masyuk; Tatyana V Masyuk; Christy E Trussoni; Nicholas E Pirius; Nicholas F LaRusso
Journal:  Hepatology       Date:  2022-02-08       Impact factor: 17.298

5.  Pasireotide does not improve efficacy of aspiration sclerotherapy in patients with large hepatic cysts, a randomized controlled trial.

Authors:  Titus F M Wijnands; Tom J G Gevers; Marten A Lantinga; René H Te Morsche; Leo J Schultze Kool; Joost P H Drenth
Journal:  Eur Radiol       Date:  2018-01-09       Impact factor: 5.315

6.  Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.

Authors:  Tatyana Masyuk; Anatoliy Masyuk; Christy Trussoni; Brynn Howard; Jingyi Ding; Bing Huang; Nicholas LaRusso
Journal:  JHEP Rep       Date:  2021-08-05

7.  Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.

Authors:  Marie C Hogan; Julie A Chamberlin; Lisa E Vaughan; Angela L Waits; Carly Banks; Kathleen Leistikow; Troy Oftsie; Chuck Madsen; Marie Edwards; James Glockner; Walter K Kremers; Peter C Harris; Nicholas F LaRusso; Vicente E Torres; Tatyana V Masyuk
Journal:  Clin J Am Soc Nephrol       Date:  2020-08-25       Impact factor: 8.237
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.